| |
SLE group (n = 69)
|
Non-SLE group (n = 73)
|
p values
|
|---|
|
Age (SD) (years)
|
75.7 ± 7.1
|
78.2 ± 6.2
|
0.02
|
|
Sex (Men/Women)
|
60 (87.0%) /9 (13.0%)
|
60 (82.2%) /13 (17.8%)
|
0.43
|
|
Comorbidities
|
|
Hypertension
|
41 (59.4%)
|
53 (72.6%)
|
0.10
|
|
Diabetes mellitus
|
17 (24.6%)
|
26 (35.6%)
|
0.15
|
|
Hyperlipidemia
|
30 (43.5%)
|
35 (47.9%)
|
0.59
|
|
Ischemic heart disease
|
28 (40.6%)
|
29 (39.7%)
|
0.92
|
|
Cerebrovascular disease
|
28 (40.6%)
|
26 (35.6%)
|
0.54
|
|
Renal disease (eGFR < 30 mL/min/1.73m2)
|
1 (1.4%)
|
1 (1.4%)
|
0.97
|
|
Antithrombotic agent
| | |
0.50
|
|
Single antiplatelets
|
32 (46.4%)
|
37 (50.7%)
| |
|
Aspirin
|
15
|
20
| |
|
Cilostazol
|
6
|
5
| |
|
Thienopyridine
|
11
|
12
| |
|
Single anticoagulants
|
16 (23.2%)
|
20 (27.4%)
| |
|
Warfarin
|
7
|
7
| |
|
DOACs
|
9
|
13
| |
|
Multiple therapy
|
21 (30.4%)
|
16 (21.9%)
| |
|
Anticoagulant + antiplatelet
|
9
|
7
| |
|
DAPT
|
10
|
8
| |
|
Triplet therapy
|
2
|
1
| |
|
Interruption of antithrombotic agents
|
55 (79.7%)
|
41 (56.1%)
|
< 0.05
|
|
Heparin replacement
|
12
|
0
| |
|
Aspirin or cilostazol replacement
|
9
|
10
| |
|
Acid blocker
| | |
< 0.05
|
|
Esomeprazole
|
40 (58.0%)
|
1 (1.4%)
| |
|
Vonoprazan
|
29 (42.0%)
|
72 (98.6%)
| |
|
Multiple lesions
|
11 (15.9%)
|
14 (19.1%)
|
0.61
|
- *SD standard deviation, DOACs direct oral anticoagulants, DAPT dual antiplatelet therapy
